Investigators compared adverse effects of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines reported in the COVID Symptom Study App with those reported during phase 3 trials.
Randomized, controlled trials in pediatric inflammatory rheumatic diseases (PiRDs) of patients who underwent bDMARDs and JAK inhibitors are reviewed.
Investigators assessed the immune response to Clostridioides difficile in immunocompromised patients.
Investigators assessed the role of cell-mediated immunity in the development of cytomegalovirus infection in patients with systemic lupus erythematosus undergoing treatment with immunosuppressants.
Investigators assessed response to vaccination with the Moderna or Pfizer-BioNTech COVID-19 vaccines in pregnant and nonpregnant lactating women.
Investigators vaccinated exclusively or partially breastfeeding women and examined their breast milk samples to determine levels of antibodies against SARS-CoV-2.
The effects of 1-year of tofacitinib therapy on bone metabolism in patients with rheumatoid arthritis were examined.
The investigators reported efficacy results from the MAXIMISE trial, the first randomized controlled trial evaluating the efficacy of a biologic agent in the treatment of axial manifestations in PsA.
Study authors conducted a systematic review and meta-analysis to assess the efficacy of Janus kinase-inhibitors and Type I interferons as potential antiviral candidates for the treatment of COVID-19.
Investigators determined whether ABO and Rh blood groups were associated with risk for SARS-CoV-2 infection and severe COVID-19 illness.
